Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANVAS: Cvac in Epithelial Ovarian Cancer
NCT01521143Phase 2Terminated
- Sponsor
- Immutep Limited
- Start
- Jan 2012
- Primary completion
- Mar 2015
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of CVac in epithelial ovarian cancer (EOC), sponsored by Immutep Limited. Started Jan 2012; status: terminated.
02
Drugs
CVac
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT01521143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01521143.